Conduit Pharmaceuticals Inc. (CDT)
Market Cap | 64.92M |
Revenue (ttm) | n/a |
Net Income (ttm) | -2.30M |
Shares Out | 73.83M |
EPS (ttm) | -7,310.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 49,202 |
Open | 0.940 |
Previous Close | 0.995 |
Day's Range | 0.860 - 1.010 |
52-Week Range | 0.630 - 25.000 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 13, 2024 |
About CDT
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/p/k/press20-2443050.jpg)
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncolo...
![](https://cdn.snapi.dev/images/v1/i/g/press4-2441359.jpg)
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO.
![](https://cdn.snapi.dev/images/v1/b/l/press6-2330524.jpg)
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual pr...
![](https://cdn.snapi.dev/images/v1/9/x/press6-2317396.jpg)
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub
SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory spac...
![](https://cdn.snapi.dev/images/v1/b/0/conf15-2252935.jpg)
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for com...
![](https://cdn.snapi.dev/images/v1/a/v/press3-2136017.jpg)
Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
SAN DIEGO and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life science ...
![](https://cdn.snapi.dev/images/v1/5/u/press5-2098615.jpg)
Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
Collaboration underscores Conduit's mission to advance promising treatments by developing assets that have already completed Phase I trials Collaboration underscores Conduit's mission to advance promi...
![](https://cdn.snapi.dev/images/v1/c/d/press3-2098667.jpg)
ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656
NEW YORK--(BUSINESS WIRE)--ClinConnect, a first-of-its-kind platform redefining how patients and clinical trials find each other, today announced a partnership with Conduit Pharmaceuticals Inc. (Nasda...
![](https://cdn.snapi.dev/images/v1/p/r/press11-2074522.jpg)
Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient mod...